Miquel Serra-Burriel
Biographic Data
| ID | 9571273 |
|---|---|
| NAME | Miquel Serra-Burriel |
| GIVEN NAMES | Miquel |
| FAMILY NAME | Serra-Burriel |
| SIGNATURE | SERRA-BURRIEL M |
| AFFILIATIONS | University of Zurich |
| VERIFIED | No |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs
LiverScreen project
This study is registered on Clinicaltrials.gov ( NCT03789825 )
Surgical procedures in inpatient versus outpatient settings and its potential impact on follow-up costs
OBJECTIVE: We examined real-world effects of cantonal legislations to direct surgery patients from the inpatient to the outpatient setting in Switzerland. METHODS: Analyses were based on claims data of the Helsana Group, a leading Swiss health insurance. The study population consisted of 13'145 (in 2014), 12'455 (in 2016), and 12'875 (in 2018) insured persons aged >18 years who had haemorrhoidectomy, inguinal hernia repair, varicose vein surgery,…
No prominent works on this page.
Surgical procedures in inpatient versus outpatient settings and its potential impact on follow-up costs
OBJECTIVE: We examined real-world effects of cantonal legislations to direct surgery patients from the inpatient to the outpatient setting in Switzerland. METHODS: Analyses were based on claims data of the Helsana Group, a leading Swiss health insurance. The study population consisted of 13'145 (in 2014), 12'455 (in 2016), and 12'875 (in 2018) insured persons aged >18 years who had haemorrhoidectomy, inguinal hernia repair, varicose vein surgery,…
LiverScreen project
This study is registered on Clinicaltrials.gov ( NCT03789825 )
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs
Medicine (4 works) · Environmental health (3 works) · Business (2 works) · Drug prices (2 works) · Economics (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Internal Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Population (2 works) · Public economics (2 works)